Scinovex
article Open AccessTop 1% cited

Challenges and Opportunities in the Development of Organometallic Anticancer Drugs

Organometallics · 2012 · Vol. 31(16) · pp. 5677–5685
Christian G. HartingerNils Metzler‐NoltePaul J. Dyson

Abstract

This review provides an introduction into the fascinating area of organometallic anticancer compounds. Although the subject dates back many years, it has witnessed considerable growth only in the past decade. A brief overview of the subject together with recent pertinent examples is provided. The properties of organometallic compounds that lend themselves to medical applications, the main current approaches used, and possible avenues for future research are identified.

Ferrocene Chemistry and ApplicationsMetal complexes synthesis and propertiesSynthesis and Biological EvaluationChemistryGroup 2 organometallic chemistrySubject (documents)NanotechnologyEngineering ethicsOrganic chemistryLibrary scienceComputer scienceEngineeringMolecule
Citations
551
FWCI
29.06
field-weighted impact
References
143
Percentile
100%
vs. same field & year
Citations per year
Cited by
References
Areneruthenium complexes as anticancer agents
Dalton Transactions · 2009 · 632 citations
Organometallic Anticancer Compounds
Journal of Medicinal Chemistry · 2010 · 1,582 citations
In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes
Journal of Medicinal Chemistry · 2005 · 769 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.